Production (Stage)
BioSyent Inc.
RX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.80% | 9.17% | 11.08% | 16.55% | 17.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.80% | 9.17% | 11.08% | 16.55% | 17.72% |
| Cost of Revenue | 23.62% | 17.93% | 23.59% | 33.61% | 32.36% |
| Gross Profit | 10.16% | 7.12% | 8.24% | 12.89% | 14.63% |
| SG&A Expenses | 33.17% | 28.84% | 6.91% | 7.14% | 9.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.09% | 32.69% | 10.96% | 13.16% | 14.79% |
| Operating Income | 43.17% | 46.71% | 11.44% | 28.30% | 27.56% |
| Income Before Tax | 9.04% | 12.87% | 11.58% | 29.23% | 33.12% |
| Income Tax Expenses | 14.47% | 19.21% | 6.37% | 18.54% | 22.37% |
| Earnings from Continuing Operations | 7.27% | 10.83% | 13.36% | 33.13% | 37.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.27% | 10.83% | 13.36% | 33.13% | 37.03% |
| EBIT | 43.17% | 46.71% | 11.44% | 28.30% | 27.56% |
| EBITDA | 45.95% | 49.02% | 9.62% | 26.12% | 25.79% |
| EPS Basic | 10.58% | 14.09% | 16.74% | 37.68% | 41.48% |
| Normalized Basic EPS | 40.92% | 47.62% | 14.90% | 33.60% | 37.37% |
| EPS Diluted | 10.28% | 14.04% | 16.76% | 38.10% | 42.28% |
| Normalized Diluted EPS | 40.59% | 47.51% | 14.92% | 33.88% | 37.79% |
| Average Basic Shares Outstanding | -3.01% | -3.05% | -3.05% | -3.32% | -3.02% |
| Average Diluted Shares Outstanding | -2.84% | -3.05% | -3.12% | -3.50% | -3.25% |
| Dividend Per Share | 8.50% | 10.79% | 8.42% | 41.17% | 107.11% |
| Payout Ratio | -0.02% | -0.03% | -0.07% | 0.03% | 0.48% |